Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2015 3
2016 1
2018 1
2019 3
2020 1
2021 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean aurora rauscher (1 results)?
Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.
Lugat A, Frampas É, Touchefeu Y, Mirallié É, Bras ML, Senellart H, Rauscher A, Fleury V, Campion L, Rohmer V, Couturier OF, Lebtahi R, Rouzet F, Ruszniewski P, Kraeber-Bodéré F, Bourgeois M, Ansquer C. Lugat A, et al. Among authors: rauscher a. Cancers (Basel). 2023 Jan 14;15(2):513. doi: 10.3390/cancers15020513. Cancers (Basel). 2023. PMID: 36672462 Free PMC article.
Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study.
Vigne J, Peyronnet D, Leenhardt J, Dubegny C, Ardisson V, Pariscoat G, Bolot C, Rauscher A, Hallouard F, Clave-Darcissac C, Clotagatide A, Odouard E, Faivre-Chauvet A, Diehl J, Houdu B, Agostini D, Morello R. Vigne J, et al. Among authors: rauscher a. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4331-4338. doi: 10.1007/s00259-021-05361-9. Epub 2021 Jun 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 34169368 Free PMC article.
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. Among authors: rauscher a. J Nucl Med. 2021 Sep 1;62(9):1221-1227. doi: 10.2967/jnumed.120.252791. Epub 2021 Feb 5. J Nucl Med. 2021. PMID: 33547213 Free PMC article.
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F. Ansquer C, et al. Among authors: rauscher a. Clin Nucl Med. 2021 Mar 1;46(3):181-186. doi: 10.1097/RLU.0000000000003450. Clin Nucl Med. 2021. PMID: 33315677
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: rauscher a. J Nucl Med. 2020 Aug;61(8):1205-1211. doi: 10.2967/jnumed.119.236000. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169921 Free PMC article. Clinical Trial.
Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: rauscher a. Prostate. 2019 Sep;79(13):1514-1522. doi: 10.1002/pros.23869. Epub 2019 Aug 17. Prostate. 2019. PMID: 31421657 Clinical Trial.
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Bodet-Milin C, et al. Among authors: rauscher a. Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214593 Free PMC article. Review.
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C. Barbaud M, et al. Among authors: rauscher a. Prostate. 2019 Apr;79(5):454-461. doi: 10.1002/pros.23751. Epub 2018 Dec 14. Prostate. 2019. PMID: 30549066
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. Among authors: rauscher a. J Nucl Med. 2016 Oct;57(10):1505-1511. doi: 10.2967/jnumed.116.172221. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230928 Free article. Clinical Trial.
15 results